Alzheimer - International Biopharmaceutical Industry

news

Cortexyme to shift focus after FDA places hold on experimental Alzheimer’s drug

Dive Brief: The Food and Drug Administration has ordered California biotech Cortexyme to stop testing of an experimental Alzheimer's disease drug, notifying the dr...

27 January 2022 news Alzheimer | Biotech

Continue Reading →

news

Medicare proposes to limit coverage of Biogen Alzheimer’s drug

Medicare will restrict coverage of Biogen's controversial Alzheimer's treatment only to patients who take part in a rigorous clinical trial, the federal government an...

14 January 2022 news Alzheimer | Biogen

Continue Reading →

news

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the Centers...

14 January 2022 news Alzheimer | blood

Continue Reading →

news

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of the ...

14 January 2022 news Alzheimer | cell

Continue Reading →

news

Biogen reserves four years for trial meant to confirm its Alzheimer’s drug works

A crucial study evaluating Biogen's approved drug for Alzheimer's disease is set to begin in May, the company disclosed Thursday, and if enrollment goes as expected, ...

16 December 2021 news Aduhelm | Alzheimer

Continue Reading →

news

GSK sets sights on brain diseases through Oxford partnership

Diseases of the brain and central nervous system have been notoriously challenging to treat, even for the world's largest and most well-resourced drug companies. But...

13 December 2021 news Alzheimer | brain diseases

Continue Reading →

news

Biogen seeking more information in investigation of Aduhelm patient’s death

Aduhelm has come under intense scrutiny since the Food and Drug Administration's controversial June approval of the drug, the first new Alzheimer's treatment in decad...

26 November 2021 news Aduhelm | Alzheimer

Continue Reading →

news

Anticipating Aduhelm’s costs, Medicare plans big jump in premiums

The decision affects Medicare Part B, which pays for health care services typically received outside of institutional settings like hospitals and nursing homes. The p...

19 November 2021 news Aduhelm | Alzheimer

Continue Reading →

news

Cortexyme plans path forward for Alzheimer’s drug that failed study

Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer's drug in another study, co...

15 November 2021 news Alzheimer | Cortexyme

Continue Reading →

news

With approval plans underway, Lilly’s next move is to test its Alzheimer’s drug against Biogen’s

With few treatment options and millions of patients in the U.S. alone, Alzheimer's has long been one of the biggest targets for drug developers. Yet, the disease has...

29 October 2021 news Aduhelm | Alzheimer

Continue Reading →